Arg-Gly-Asp-Ser

• CAT Number: I005424
• CAS Number: 91037-65-9
• Molecular Formula: C15H27N7O8
• Molecular Weight: 433.4
• Purity: ≥95%
• Target: Integrin
• Solubility: DMSO: ≥ 55 mg/mL
• Storage: Desiccate at -20C
• InChIKey: NNRFRJQMBSBXGO-CIUDSAMLSA-N

Arg-Gly-Asp-Ser (CAT: I005424) is a peptide sequence derived from the extracellular matrix protein fibronectin. It is known for its ability to bind to integrin receptors, particularly integrin αvβ3, which is expressed on the surface of various cells including endothelial cells and some cancer cells. The sequence Arg-Gly-Asp (RGD) is a recognition motif for integrins and plays a crucial role in cell adhesion, migration, and signaling. By binding to integrins, Arg-Gly-Asp-Ser can modulate cell behavior, including angiogenesis (formation of new blood vessels) and tumor growth. It has been extensively studied in the development of targeted therapies for cancer and other pathological conditions where integrin signaling is involved.

Reference

[1]. Grigoriou V, et al. Apoptosis and survival of osteoblast-like cells are regulated by surface attachment. J Biol Chem. 2005 Jan 21;280(3):1733-9. 


[2]. Moon C, et al. Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways. Respir Res. 2009 Mar 9;10:18. 


[3]. Yin X, et al. Synthetic RGDS peptide attenuated lipopolysaccharide/D-galactosamine-induced fulminant hepatic failure in mice. J Gastroenterol Hepatol. 2014 Jun;29(6):1308-15. 


[4]. Aguzzi MS, et al. Intracellular targets of RGDS peptide in melanoma cells. Mol Cancer. 2010 Apr 22;9:84. 


[5]. He H, et al. Inhibitory effect of RGDS peptide on experimental choroidal neovascularization in a rat model. Zhonghua Yan Ke Za Zhi. 2006 Sep;42(9):825-31.